Richard Moss

List of Publications by Year
in descending order

149 papers	15,741 citations	23567 58 h-index	16650 123 g-index
153 all docs	153 docs citations	153 times ranked	9915 citing authors

#	Article	IF	Citations
1	Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2022, 21, 136-142.	0.7	10
2	Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons. Journal of Allergy and Clinical Immunology, 2021, 147, 1212-1214.	2.9	5
3	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1909-1930.e4.	3.8	15
4	Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 644-645.	5.6	2
5	Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity. EBioMedicine, 2020, 60, 103035.	6.1	4
6	Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulmonary Therapy, 2020, 6, 303-313.	2.2	7
7	Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. Pediatric Pulmonology, 2020, 55, 929-938.	2.0	16
8	Manifestations of pulmonary aspergillosis in pediatrics. Current Opinion in Pediatrics, 2020, 32, 389-394.	2.0	10
9	Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function. Journal of Cystic Fibrosis, 2019, 18, 64-70.	0.7	20
10	Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Current Opinion in Pediatrics, 2018, 30, 372-377.	2.0	42
11	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis, 2018, 17, 503-510.	0.7	14
12	Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. Mycopathologia, 2018, 183, 263-272.	3.1	18
13	Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. Scientific Reports, 2018, 8, 16233.	3.3	7
14	The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatric Pulmonology, 2018, 53, S75-S85.	2.0	39
15	Susceptibility of Candida albicans from Cystic Fibrosis Patients. Mycopathologia, 2017, 182, 863-867.	3.1	1
16	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respiratory Medicine,the, 2017, 5, 107-118.	10.7	235
17	Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. Mycopathologia, 2017, 182, 315-318.	3.1	13
18	P255â€…Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation. , 2017, , .		1

#	Article	IF	Citations
19	The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. PLoS ONE, 2017, 12, e0175486.	2.5	7
20	Allergic Bronchopulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2016, 2, 17.	3.5	55
21	Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF. Journal of Allergy and Clinical Immunology, 2016, 137, AB29.	2.9	1
22	Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis. Journal of Allergy and Clinical Immunology, 2016, 138, 1195-1196.	2.9	6
23	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. Antimicrobial Agents and Chemotherapy, 2016, 60, 2180-2184.	3.2	16
24	Treating allergic bronchopulmonary aspergillosis: the way forward. European Respiratory Journal, 2016, 47, 385-387.	6.7	17
25	Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. European Respiratory Journal, 2016, 47, 177-185.	6.7	39
26	The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2016, 137, 436-443.e9.	2.9	47
27	Earth Moverâ€™s Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations. PLoS ONE, 2016, 11, e0151859.	2.5	82
28	Recent advances in cystic fibrosis. Current Opinion in Pediatrics, 2015, 27, 317-324.	2.0	8
29	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
30	Fungi in Cystic Fibrosis and Nonâ€“Cystic Fibrosis Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 207-216.	2.1	32
31	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	10.7	197
32	Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Journal of Cystic Fibrosis, 2015, 14, 219-227.	0.7	90
33	Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 474-481.	0.7	48
34	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. PLoS ONE, 2015, 10, e0134692.	2.5	77
35	Basophil Activation Is a Reliable Biomarker Of Allergic Bronchopulmonary Aspergillosis (ABPA) In CF: One Year Results Of a Longitudinal Cohort Study. Journal of Allergy and Clinical Immunology, 2014, 133, AB58.	2.9	1
36	Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. European Respiratory Journal, 2014, 43, 1487-1500.	6.7	82

#	Article	IF	Citations
37	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	10.7	372
38	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	10.7	301
39	A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor. PLoS ONE, 2014, 9, e88564.	2.5	49
40	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 2013, 43, 850-873.	2.9	666
41	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 69-75.	1.4	39
42	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 241-248.	0.7	102
43	Current treatment options for invasive aspergillosis. Drugs of Today, 2013, 49, 213.	1.1	6
44	Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic Fibrosis. Journal of Pediatrics, 2013, 162, 676-680.	1.8	40
45	Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation. PLoS ONE, 2013, 8, e66955.	2.5	44
46	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation. Thorax, 2012, 67, 12-18.	5.6	466
47	The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Annals of the New York Academy of Sciences, 2012, 1272, 49-57.	3.8	26
48	Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA. Journal of Allergy and Clinical Immunology, 2012, 129, AB139.	2.9	0
49	Fungi and allergic lower respiratory tract diseases. Journal of Allergy and Clinical Immunology, 2012, 129, 280-291.	2.9	398
50	Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. Journal of Cystic Fibrosis, 2012, 11, 502-510.	0.7	40
51	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
52	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	1.8	36
53	Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 627-634.	5.6	71
54	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920

#	Article	IF	Citations
55	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis. JAMA Pediatrics, 2011, 165, 847.	3.0	199
56	Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2010, 16, 598-603.	2.6	71
57	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatric Pulmonology, 2010, 45, 934-944.	2.0	51
58	Safety, Tolerability, and Efficacy of High-Frequency Chest Wall Oscillation in Pediatric Patients With Cerebral Palsy and Neuromuscular Diseases: An Exploratory Randomized Controlled Trial. Journal of Child Neurology, 2010, 25, 815-821.	1.4	59
59	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation. New England Journal of Medicine, 2010, 363, 1991-2003.	27.0	741
60	Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5779-5783.	7.1	90
61	Infection, Inflammation, and the Downward Spiral of Cystic Fibrosis Lung Disease. Journal of Pediatrics, 2009, 154, 162-163.	1.8	10
62	Cystic fibrosis HRCT scores correlate strongly with pseudomonas infection. Pediatric Pulmonology, 2009, 44, 1107-1117.	2.0	27
63	Study Of Sublingual Immunotherapy In Subjects With Dermatophagoides Farniae And Timothy Grass Allergy. Journal of Allergy and Clinical Immunology, 2009, 123, S126-S126.	2.9	0
64	Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 1-8.	0.7	18
65	Management of allergic aspergillosis. Current Allergy and Asthma Reports, 2008, 8, 433-439.	5.3	3
66	Management of allergic aspergillosis. Current Fungal Infection Reports, 2008, 2, 87-93.	2.6	4
67	Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4335-4339.	7.1	126
68	Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial. Human Gene Therapy, 2007, 18, 726-732.	2.7	239
69	No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 57-66.	2.9	81
70	A PILOT STUDY OF POLYSOMNOGRAPHY TO EVALUATE EFFECTIVENESS OF AIRWAY CLEARANCE THERAPIES IN PEDIATRIC PATIENTS WITH CEREBRAL PALSY AND NEUROMUSCULAR DISORDERS. Chest, 2007, 132, 609A.	0.8	1
71	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 610-623.	2.0	88
72	Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients. Pancreas, 2006, 32, 258-263.	1.1	39

#	Article	IF	Citations
73	Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Clinical and Molecular Allergy, 2006, 4, 11.	1.8	45
74	Fully Automated System for Three-Dimensional Bronchial Morphology Analysis Using Volumetric Multidetector Computed Tomography of the Chest. Journal of Digital Imaging, 2006, 19, 132-139.	2.9	26
75	Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy. Medical Mycology, 2006, 44, S269-S272.	0.7	20
76	High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4628-4633.	7.1	235
77	Dornase Alfa Reduces Air Trapping in Children With Mild Cystic Fibrosis Lung Disease. Chest, 2005, 128, 2327-2335.	0.8	96
78	Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation. Chest, 2005, 128, 2316-2326.	0.8	140
79	Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis. American Journal of Medical Genetics, Part A, 2005, 133A, 103-105.	1.2	2
80	Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatric Pulmonology, 2005, 39, 209-218.	2.0	55
81	Diagnostic Testing by CFTR Gene Mutation Analysis in a Large Group of Hispanics. Journal of Molecular Diagnostics, 2005, 7, 289-299.	2.8	40
82	Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Medical Mycology, 2005, 43, 203-206.	0.7	78
83	Stevens et al. (2003;â€‰37[Suppl 3]:S225â€“64). Clinical Infectious Diseases, 2004, 38, 158-158.	5.8	24
84	Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clinical and Experimental Immunology, 2004, 135, 358-360.	2.6	20
85	Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatric Pulmonology, 2004, 38, 396-405.	2.0	73
86	Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. Chest, 2004, 125, 509-521.	0.8	351
87	Advances against Aspergillosis. Clinical Infectious Diseases, 2003, 37, S155-S156.	5.8	20
88	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	5.6	300
89	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosisâ€”State of the Art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases, 2003, 37, S225-S264.	5.8	658
90	Composite Spirometricâ€“Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 588-593.	5.6	78

#	Article	IF	Citations
91	A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy, 2002, 13, 1349-1359.	2.7	239
92	Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis. Chest, 2002, 121, 55-63.	0.8	158
93	Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Journal of Pediatrics, 2001, 138, 553-559.	1.8	71
94	A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease. Human Gene Therapy, 2001, 12, 1907-1916.	2.7	219
95	Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients. Chest, 2001, 120, 107S-113S.	0.8	84
96	Comprehensive Mutation Screening in a Cystic Fibrosis Center. Pediatrics, 2001, 107, 280-286.	2.1	28
97	Novel cystic fibrosis mutation L1093P: Functional analysis and possible Native American origin. Human Mutation, 2000, 15, 208-208.	2.5	5
98	Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clinical and Experimental Immunology, 2000, 120, 518-525.	2.6	107
99	Pulmonary Sequelae of Bronchopulmonary Dysplasia Survivors. American Journal of Roentgenology, 2000, 174, 1323-1326.	2.2	88
100	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Chest, 1999, 115, 364-370.	0.8	143
101	Safety and Biological Efficacy of an Adeno-Associated Virus Vector-Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus. Laryngoscope, 1999, 109, 266-274.	2.0	193
102	Two novel mutations in a cystic fibrosis patient of Chinese origin. Human Genetics, 1999, 104, 511-515.	3.8	33
103	Comparison of a Î²-lactam alone versus Î²-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics, 1999, 134, 413-421.	1.8	124
104	Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Journal of Gene Medicine, 1999, 1, 13-21.	2.8	27
105	Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California.. American Journal of Tropical Medicine and Hygiene, 1999, 61, 850-859.	1.4	36
106	Spirometer-Triggered High Resolution Computed Tomography (HRCT) of the Chest, Clinical Score, and Pulmonary Function Measurements in Cystic Fibrosis (CF) Patients before and after Treatment for a Pulmonary Exacerbation. Pediatric Research, 1999, 45, 355A-355A.	2.3	1
107	Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet, The, 1998, 351, 1702-1703.	13.7	220
108	Bone acquisition and loss in children and adults with cystic fibrosis: A longitudinal study. Journal of Pediatrics, 1998, 133, 18-27.	1.8	148

#	Article	IF	Citations
109	A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California. Human Gene Therapy, 1998, 9, 889-909.	2.7	95
110	A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Human Molecular Genetics, 1998, 7, 729-735.	2.9	92
111	Activation of Eosinophils in the Airways of Lung Transplantation Patients. Chest, 1997, 112, 1180-1183.	0.8	16
112	Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clinical and Experimental Immunology, 1996, 106, 374-388.	2.6	80
113	Clinical protocol: AAV-CFTR for the treatment of chronic sinusitis in CF patients.. Clinical Pharmacology and Therapeutics, 1996, 59, 174-174.	4.7	0
114	Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1914-1917.	5.6	67
115	Alternative Pharmacotherapies for Steroid-Dependent Asthma. Chest, 1995, 107, 817-825.	0.8	24
116	Vocal Cord Dysfunction Syndrome and â€œSteroid-Dependentâ€•Asthmatics. Chest, 1995, 108, 1772-1773.	0.8	0
117	Osteopenia in adults with cystic fibrosis. American Journal of Medicine, 1994, 96, 27-34.	1.5	141
118	Deficiency of IgG4 in children: Association of isolated IgG4 deficiency with recurrent respiratory tract infection. Journal of Pediatrics, 1992, 120, 16-21.	1.8	52
119	Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 1991, 87, 78-88.	2.9	54
120	IgE antibodies in tick bite-induced anaphylaxis. Journal of Allergy and Clinical Immunology, 1991, 88, 968-970.	2.9	20
121	Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 1990, 9, 7-18.	2.0	42
122	Late Pulmonary Sequelae of Bronchopulmonary Dysplasia. New England Journal of Medicine, 1990, 323, 1793-1799.	27.0	515
123	Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Lancet, The, 1990, 335, 1077-1078.	13.7	82
124	Suppression of the late cutaneous response by immunotherapy1. Journal of Allergy and Clinical Immunology, 1989, 83, 101-109.	2.9	61
125	Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.. Journal of Clinical Investigation, 1989, 84, 1794-1804.	8.2	37
126	Reproducibility of skin prick testing with allergen extracts from different manufacturers. Allergy: European Journal of Allergy and Clinical Immunology, 1988, 43, 458-463.	5.7	21

#	Article	IF	Citations
127	Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. Journal of Pediatrics, 1988, 112, 547-554.	1.8	143
128	486 Defective antibody-mediated opsonization of pseudomonas aeruginosa (PA) in cystic fibrosis (CF): An isotype-dependent deffect?. Journal of Allergy and Clinical Immunology, 1988, 81, 289.	2.9	0
129	493 Suppression of the Late Cutaneous Response (LCR) by immunotherapy (IT). Journal of Allergy and Clinical Immunology, 1988, 81, 291.	2.9	1
130	Hypergammaglobulinemia in Cystic Fibrosis. Chest, 1987, 91, 522-526.	0.8	26
131	Interobserver Variance in Clinical Scoring for Cystic Fibrosis. Chest, 1987, 91, 878-882.	0.8	22
132	Altered Antibody Isotype in Cystic Fibrosis: Impaired Natural Antibody Response to Polysaccharide Antigens. Pediatric Research, 1987, 22, 708-713.	2.3	33
133	Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgG1 with clinical response. Journal of Allergy and Clinical Immunology, 1987, 79, 387-398.	2.9	43
134	Immunoglobulin E antibodies in young children with possible allergic symptoms. Journal of Pediatrics, 1987, 110, 738-740.	1.8	3
135	Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. Journal of Allergy and Clinical Immunology, 1987, 80, 798-802.	2.9	7
136	Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy. Journal of Allergy and Clinical Immunology, 1986, 78, 590-600.	2.9	182
137	Cow's milk allergy in breast-fed infants: The role of allergen and maternal secretory IgA antibody. Journal of Allergy and Clinical Immunology, 1986, 77, 341-347.	2.9	153
138	Supraventricular Tachycardia in Patients with Cystic Fibrosis. Chest, 1986, 90, 239-242.	0.8	16
139	Altered Antibody Isotype in Cystic Fibrosis. Possible Role in Opsonic Deficiency. Pediatric Research, 1986, 20, 453-459.	2.3	49
140	Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics, 1986, 78, 473-9.	2.1	58
141	8 Once a day theophylline (uniphyl) for treatment of patients with asthma (AS) and cystic fibrosis(CF). Journal of Allergy and Clinical Immunology, 1985, 75, 106.	2.9	0
142	282 A quantitative immunoenzymatic assay for grass pollen-specific IgG antibodies. Journal of Allergy and Clinical Immunology, 1985, 75, 175.	2.9	0
143	Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. Journal of Allergy and Clinical Immunology, 1985, 76, 172-176.	2.9	25
144	Allergy to semisynthetic penicillins in cystic fibrosis. Journal of Pediatrics, 1984, 104, 460-466.	1.8	81

#	Article	IF	Citations
145	Grass pollen immunotherapy: A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. Journal of Allergy and Clinical Immunology, 1984, 73, 283-290.	2.9	112
146	37 Infantile allergy and milk-specific antibodies in breast milk. Journal of Allergy and Clinical Immunology, 1983, 71, 98.	2.9	1
147	124 Grass pollen immunotherapy, clinical and immunologic effects in a double-blind placebo-controlled study. Journal of Allergy and Clinical Immunology, 1983, 71, 119.	2.9	5
148	125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. Journal of Pediatrics, 1981, 99, 215-222.	1.8	41
149	Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. The American Review of Respiratory Disease, 1980, 121, 23-9.	2.9	52